Fri Sep 06 05:10:55 UTC 2024: – Inovio Pharmaceuticals, Inc. has been given an average recommendation of “Moderate Buy” by analysts covering the stock, with two analysts rating it as hold and three as buy.
– The average 12-month price objective for the stock is $44.00.
– The company recently reported earnings per share of ($1.19) for the quarter, missing expectations.
– Institutional investors and hedge funds have been adding to or reducing their stakes in the stock.
– Inovio Pharmaceuticals focuses on the development of DNA medicines to treat diseases such as HPV, cancer, and infectious diseases.

Read More